Gritstone bio, Inc. is a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines. The company leverages its innovative vectors and payloads to train multiple arms of the immune system to attack critical disease targets. Independently and with its collaborators, Gritstone is advancing a portfolio of product candidates to treat and prevent viral diseases and solid tumors in pursuit of improving patient outcomes and eliminating disease.